Dong Sung Pharmaceutical Faces Internal Strife Over Rehabilitation Process Korean mid-sized drugmaker Dong Sung Pharmaceutical is once again mired in internal conflict over its rehabilitation plan, raising concerns that its efforts to

Korean mid-sized drugmaker Dong Sung Pharmaceutical is once again mired in internal conflict over its rehabilitation plan, raising concerns that its efforts to resume stock trading may be delayed.
#dongsung #pharmaceutical #drug #drugmaker #it #itchosun #chosun #SouthKorea #Korea #NewsUpdate

Bloomberg: #UK #drugmaker #AstraZeneca plans to invest $50 billion in the US before 2030, ratcheting up spending alongside other #European #pharmaceutical #companies ahead of looming #tariffs on #imported #medicines.

#novartis #kisqali #full-year-earnings-forecast #second-quarter-sales #us-tariff-threat #tariff-hike #prescription-drug #pharmaceutical-industry #drugmaker #earnings-outlook #2025-economy #samsung-swiss #market-outlook #income-guidance

#pharmaceutical-industry #pharma-stock #stock-performance #market-outperformance #trump-administration #trade-policy #trade-war #tariff #tariff-threat #200-percent-tariff #drugmaker #regulatory-policy #grace-period #deregulation #market-forecast #investor-sentiment

COVID19, Russia Ukraine War, Pandemic influenza (H1N1 or similar): is there a warning pattern in central Europe?? | ResearchGate Read 29 answers by scientists with 2 recommendations from their colleagues to the question asked by Salvatore Vicidomini on Mar 22, 2023

#US cancels more than $700 million funding for #Moderna #bird #flu #vaccine #HPAI ..

www.researchgate.net/post/COVID19... ..

#Trump
#drugmaker
#Biden
#DOGE

Bangladeshi pharmaceutical companies are closely monitoring developments following the Trump administration's move to explore imposing tariffs on pharmaceutical imports, a decision that could reshape trade dynamics with the United States.

Link in Comments

#drugmaker #UStariffs #TBSNews

S. Korea fines pharma giant Celltrion for unfair business practices - Yes Punjab News South Korea fines pharmaceutical giant Celltrion 435 million won for unfair business practices benefiting its affiliate, Celltrion Healthcare.

S. Korea fines pharma giant Celltrion for unfair business practices
yespunjab.com?p=68655

#SouthKorea #Celltrion #AntitrustFine #FairTradeCommission #UnfairBusinessPractices #FTC #Drugmaker #CelltrionHealthcare